Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 177, Issue 13, Pages 2889-2903Publisher
WILEY
DOI: 10.1111/bph.15081
Keywords
-
Categories
Funding
- Fondazione Umberto Veronesi
- Horizon 2020 Framework Programme [800924]
- Ministero della Salute [RF2016-02362288, GR-2013-02356568, 5x1000 2015]
- Ricerca Corrente OPBG
- Associazione Italiana per la Ricerca sul Cancro [21147, IG 2017, 19920]
Ask authors/readers for more resources
Immune checkpoint inhibitors have revolutionized cancer therapy leading to exceptional success. However, there is still the need to improve their efficacy in non-responder patients. Natural killer (NK) cells represent the first line of defence against tumours, due to their ability to release immunomodulatory cytokines and kill target cells that have undergone malignant transformation. Harnessing NK cell response will open new possibilities to improve control of tumour growth. In this respect inhibitory checkpoints expressed on these innate lymphocytes represents a promising target for next-generation immunotherapy. In this review, we will summarize recent evidences on the expression of NK cells receptors in cancer, with a focus on the inhibitory checkpoint programmed cell death protein 1 (PD-1). We will also highlight the strength and limitations of the blockade of PD-1 inhibitory pathway and suggest new combination strategies that may help to unleash more efficiently NK cell anti-tumour response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available